{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:42:45Z","timestamp":1760085765096,"version":"build-2065373602"},"reference-count":20,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,9,17]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The main goal of treatment in relapsing-remitting multiple sclerosis (RRMS) is to reduce the occurrence of relapses. However, little is known about the natural history of relapse recovery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We accessed data from DECIDE (n=1841), a phase 3 trial. We investigated factors associated with time to relapse recovery (defined as a return of the Expanded Disability Status Scale (EDSS) score to the pre-relapse level or lower), relapse severity (0.5, 1.0, or &gt;1.0 EDSS score change) and the new concept of 'acute clinical events with stable MRI' (ACES). Variables used were age, sex, disease duration, treatment arm, pre-relapse EDSS, corticosteroid use, number of relapses prior to study enrolment, MRI activity, relapse severity and affected functional system (FS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 430 first relapses, of which 405 (94.2%) recovered during follow-up, 400 (93%) by 1 year (median time to recovery of 71 days, 95% CI 66 to 75 days). More severe relapses and relapses involving the bowel and bladder FS took a longer time to recover. Corticosteroids hastened the recovery of relapses but did not influence eventual relapse recovery. ACES occurred in 38% of relapses and was more frequent in older people and participants treated with daclizumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Most relapses (94.2%) recover, but the process of recovery can take up to 1 year and depends mostly on relapse severity. Our findings challenge the concept of 3-month and 6-month confirmed disability progression as reliable markers of permanent disability in RRMS trials. ACES occurs frequently and is associated with age.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jnnp-2025-336660","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:10:34Z","timestamp":1760083834000},"page":"jnnp-2025-336660","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Extended window of relapse recovery in RRMS: an analysis of the DECIDE dataset"],"prefix":"10.1136","author":[{"given":"Jop","family":"Mostert","sequence":"first","affiliation":[{"name":"Neurology, Rijnstate Hospital Arnhem, Arnhem, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-5864","authenticated-orcid":false,"given":"Eva M","family":"Strijbis","sequence":"additional","affiliation":[{"name":"Neurology, Amsterdam UMC - Locatie VUMC, Amsterdam, Noord-Holland, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"D\u2019Haeseleer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Moral","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Sant Joan Desp\u00ed Mois\u00e8s Broggi, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Brieva","sequence":"additional","affiliation":[{"name":"Neurology, Hospital Universitari Arnau de Vilanova, Lleida, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacynthe","family":"Comtois","sequence":"additional","affiliation":[{"name":"M\u00e9decine, service de neurologie, H\u00f4pital Maisonneuve-Rosemont, Montreal, Quebec, Canada"},{"name":"Neurosciences, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavle","family":"Repovic","sequence":"additional","affiliation":[{"name":"Swedish Neuroscience Institute, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D","family":"Bowen","sequence":"additional","affiliation":[{"name":"Swedish Neuroscience Institute, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[{"name":"UAB School of Public Health, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9972-5092","authenticated-orcid":false,"given":"Marcus","family":"Koch","sequence":"additional","affiliation":[{"name":"Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2025101001101911000_jnnp-2025-336660v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1401483"},{"key":"2025101001101911000_jnnp-2025-336660v1.2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320609"},{"key":"2025101001101911000_jnnp-2025-336660v1.3","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jamaneurol.2024.1961","article-title":"Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis","volume":"81","author":"Gavoille","year":"2024","journal-title":"JAMA Neurol"},{"key":"2025101001101911000_jnnp-2025-336660v1.4","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025101001101911000_jnnp-2025-336660v1.5","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016"},{"key":"2025101001101911000_jnnp-2025-336660v1.6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","article-title":"Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis","volume":"82","author":"M\u00fcller","year":"2025","journal-title":"JAMA Neurol"},{"key":"2025101001101911000_jnnp-2025-336660v1.7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23863"},{"key":"2025101001101911000_jnnp-2025-336660v1.8","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1177\/13524585231202320","article-title":"Relapse recovery in relapsing\u2013remitting multiple sclerosis: An analysis of the CombiRx dataset","volume":"29","author":"Koch","year":"2023","journal-title":"Mult Scler"},{"key":"2025101001101911000_jnnp-2025-336660v1.9","first-page":"e1334","article-title":"Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum","volume":"97","author":"Koch","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025101001101911000_jnnp-2025-336660v1.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330887"},{"key":"2025101001101911000_jnnp-2025-336660v1.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501481"},{"key":"2025101001101911000_jnnp-2025-336660v1.12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20703"},{"key":"2025101001101911000_jnnp-2025-336660v1.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"2025101001101911000_jnnp-2025-336660v1.14","unstructured":"R Core Team . R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2024."},{"key":"2025101001101911000_jnnp-2025-336660v1.15","doi-asserted-by":"crossref","first-page":"106507","DOI":"10.1016\/j.msard.2025.106507","article-title":"Multiple sclerosis relapse incomplete recovery and associated factors - a systematic review and meta-analysis","volume":"100","author":"Ladeira","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"2025101001101911000_jnnp-2025-336660v1.16","doi-asserted-by":"crossref","unstructured":"Filippini G , Brusaferri F , Sibley WA , et al . Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000. doi:10.1002\/14651858.CD001331","DOI":"10.1002\/14651858.CD001331"},{"key":"2025101001101911000_jnnp-2025-336660v1.17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1212\/WNL.40.6.971","article-title":"Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group","volume":"40","author":"Noseworthy","year":"1990","journal-title":"Neurology (ECronicon)"},{"key":"2025101001101911000_jnnp-2025-336660v1.18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.4.859"},{"key":"2025101001101911000_jnnp-2025-336660v1.19","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1212\/01.wnl.0000313034.46883.16","article-title":"Disability as an outcome in MS clinical trials","volume":"71","author":"Ebers","year":"2008","journal-title":"Neurology (ECronicon)"},{"key":"2025101001101911000_jnnp-2025-336660v1.20","first-page":"e1560","article-title":"Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis","volume":"97","author":"Koch","year":"2021","journal-title":"Neurology (ECronicon)"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-336660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:10:38Z","timestamp":1760083838000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-336660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":20,"alternative-id":["10.1136\/jnnp-2025-336660"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-336660","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}